University of Washington (1990), Biochemistry
Graduate School
University of California-San Diego (1996), Biology

Research Interest

  • Breast Cancer
  • Cancer Therapeutics
  • Hepatocellular Carcinoma
  • Tumor Suppressors


Featured Publications LegendFeatured Publications

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES Cell Cycle 2012 Jul 11 14 2756-61
Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK Breast Cancer Res. Treat. 2012 Jun 133 3 1009-24
RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage.
McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES Gastroenterology 2011 Oct 141 4 1439-50
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.
Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES Am. J. Pathol. 2011 Sep 179 3 1171-8
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.
Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES Endocr. Relat. Cancer 2011 Jun 18 3 333-45
RB deletion disrupts coordination between DNA replication licensing and mitotic entry in vivo.
Bourgo RJ, Ehmer U, Sage J, Knudsen ES Mol. Biol. Cell 2011 Apr 22 7 931-9

Honors & Awards

  • Hearin Distinguished Lecture
  • JP Minton Award, American Cancer Society
  • Kimmel Scholar Award